New research reveals that patients who come off blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who end traditional lifestyle plans.
Published data in a leading medical journal demonstrates that while overweight individuals can lose substantial amounts of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People using these treatments must be aware of the danger of quick weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain means a return to original weight within about 18 months.
Weighing Approaches
The study, which examined 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through dieting typically see a more gradual creep back—around 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Experts believe the mechanism of the injections explains the accelerated rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in hunger is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
The NHS advise the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the treatment should be considered life-long.
This opinion is reinforced by drug manufacturers, who note that the findings "highlight the long-term character of obesity," akin to managing diseases like diabetes.
Patient Testimonies
People who have stopped the jabs describe a intense return of cravings.
"I experienced a switch flipping and you're instantly ravenous," recalled one woman.
This challenge is worsened if patients have not developed permanent lifestyle or habit changes during treatment.
Significant Adoption
Figures suggest that millions of people in the UK have used these injections in the last 12 months, with desire remaining high.
- Use is more common among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are effective tools for weight loss, they are not a standalone cure and maintained weight loss likely depends on integrated behavioural changes.
